Get started
Author

Simon Udovica

Observed name: S. Udovica
ORCID: 0000-0001-6490-4568
Observed ORCID: 0000-0001-6490-4568
OpenAlex ID: A5021299330
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancer
2023 · Maximilian Marhold, Simon Udovica, et al. · OncoImmunology · 40
Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
2019 · H. Taghizadeh, M. Marhold, et al. · OncoImmunology · 35
PDF
Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer
2020 · Erwin Tomasich, Thais Topakian, et al. · Translational research · 17
PDF
Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials
2026 · Simon Udovica, Rupert Bartsch, et al. · npj Breast Cancer · 8
PDF
Synthetic lethal combinations of low-toxicity drugs for breast cancer identifiedin silicoby genetic screens in yeast
2018 · Maximilian Marhold, Erwin Tomasich, et al. · Oncotarget · 5
PDF
MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice
2022 · Maximilian Marhold, Simon Udovica, et al. · Cancers · 4
PDF
High mortality in patients with active malignancy and severe COVID-19: Results from an Austrian multicenter registry during the first period of the COVID-19 pandemic
2022 · Simon Udovica, Nino Müser, et al. · memo - Magazine of European Medical Oncology · 3
PDF
Abstract P3-06-10: Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)
2023 · Maximilian Marhold, Simon Udovica, et al. · Cancer Research · 2
Neurotoxicity as a rare side effect of immune checkpoint inhibitors. A case report and review of the literature
2022 · Simon Udovica, Kathrin Strasser-Weippl, et al. · memo - Magazine of European Medical Oncology · 2
ESMO 2025: Highlights in breast cancer
2026 · Amelie Sandner, Simon Udovica, et al. · memo - Magazine of European Medical Oncology · 1
PDF
ESMO 2024: highlights in breast cancer
2025 · Simon Udovica, Muna Ferner, et al. · memo - Magazine of European Medical Oncology · 1
PDF
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report
2023 · Clemens Petrasch, Simon Udovica, et al. · memo - Magazine of European Medical Oncology · 1
Retrospective Analysis of Real-World Elacestrant Use in Two Large Austrian Cancer Centers
2026 · Lisa Vesenmayer, Simon Udovica, et al. · Breast Care
PDF
Supplemental Material for: Retrospective analysis of real-world elacestrant use in two large Austrian cancer centers
2026 · figshare admin karger, Lisa Vesenmayer, et al. · Figshare
AI-assisted continuous-time modelling of metastatic breast cancer reveals subtype-specific spatiotemporal organ interactions
2026 · Marc Vaisband, Gabriel Rinnerthaler, et al. · medRxiv
Chemotherapy-induced ileus and gastrointestinal hemorrhage following therapy with BrECADD for Hodgkin lymphoma: A case report
2025 · Karl Mayrhofer, Simon Udovica · Tumor Discovery
ASH 2024: highlights in multiple myeloma
2025 · Simon Udovica, Martin Schreder · memo - Magazine of European Medical Oncology
Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches
2023 · Simon Udovica, Kathrin Strasser-Weippl · memo - Magazine of European Medical Oncology
Evidence for neuroendocrine progenitor cells in a transgene mouse model of prostate cancer
2016 · Simon Udovica, Alexander Otahal, et al. · Endocrine Abstracts
Abstract 2407: Neuroendocrine and luminal progenitors drive cancer progression in prostate cancer
2016 · Maximilian Marhold, Erwin Tomasich, et al. · Cancer Research
Works count: 20
Citation count: 119
H-index: 5
I10-index: 3
Year
Topic
Type